Amendments to the Claims

Please cancel Claims 3, 6, 8-10, 14, 15, 18, 20-22, 26, 28-30 and 32-35. Please amend Claims 1, 7, 12, 19, 24, 27 and 36. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A compound represented by the formula:



wherein

R^1 is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons; ~~and~~

R^2 is an aliphatic chain having 10 to 18 carbons;

R^3 is a cyclic tertiary amine; and

R^4 is an *in vivo* hydrolyzable group.

2. (Original) The compound of claim 1 wherein R^3 is pyrrolidino.

3. (Cancelled)

4. (Original) The compound of claim 1 wherein R^1 is 4-hydroxyphenyl.

5. (Original) The compound of claim 1 wherein R^1 is 3,4-ethylenedioxy.

6. (Canceled)

7. (Currently Amended) A method for treating a patient having ~~sphingolipidosis by reducing glycosphingolipid synthesis~~ Gaucher's disease, Tay Sachs disease, Fabry's disease, Sandhoff disease or GM1 gangliosidosis, comprising the step of administering to the patient a therapeutically effective amount of the compound of Claim 1 or pharmaceutically acceptable salts thereof.

8-11. (Cancelled)

12. (Currently Amended) A compound selected from the group consisting of the formula:



wherein

R^1 is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons; ~~and~~

R^2 is an aliphatic chain having 10 to 18 carbons;

R^3 is a cyclic tertiary amine;

R^4 is an *in vivo* hydrolyzable group or a hydrogen; and

R^6 is an *in vivo* hydrolyzable group.

13. (Original) The compound of claim 12 wherein R^3 is pyrrolidino.

14-15. (Cancelled)

16. (Original) The compound of claim 12 wherein R^1 is 4-hydroxyphenyl.

17. (Original) The compound of claim 12 wherein R^1 is 3,4-ethylenedioxy.

18.(Cancelled)

19. (Currently Amended) A method for treating a patient having ~~sphingolipidosis by reducing glycosphingolipid synthesis~~ Gaucher's disease, Tay Sachs disease, Fabry's disease. Sandhoff disease or GM1 gangliosidosis, comprising the step of administering to the patient a therapeutically effective amount of the compound of Claim 12 or pharmaceutically acceptable salts thereof.

20-23. (Cancelled)

24.(Currently Amended) A compound selected from the group consisting of the formulas:



and



wherein

n is an integer from about 1 to about 19;

R_2 is an aliphatic chain having 10 to 18 carbon atoms; and

R_3 is a cyclic tertiary amine.

25. (Original) The compound of claim 24 wherein R^3 is pyrrolidino.

26. (Cancelled)

27. (Currently Amended) A method for treating a patient having ~~sphingolipidosis by reducing glycosphingolipid synthesis~~ Gaucher's disease, Tay Sachs disease, Fabry's disease, Sandhoff disease or GM1 gangliosidosis, comprising the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of the formulas:



and



or pharmaceutically acceptable salts thereof, wherein

n is an integer from about 1 to about 19;

R_2 is an aliphatic chain having 10 to 18 carbon atoms; and

R_3 is a cyclic tertiary amine.

28-35. (Cancelled)

36. (Currently Amended) The compound of Claim [[14]] 12 wherein hydrolyzable groups represented R^4 and R^6 are independently selected from the group consisting of an acetyl, -$CO(CH_2)CH_3$ and



, wherein R^5 is an alkyl group.